Spyre Therapeutics, Inc.

Analogous to a dividend being declared/approved in one period and paid out in another, the liability was recorded at the date of approval, June 22, 2023, as a common stock dividend, returning capital to the Legacy Stockholders.

SEC original ↗Spyre Therapeutics, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Accrued interest receivable on available-for-sale debt securities as of June 30, 2026 and December 31, 2025, was $ 5.8 million and $ 4.5 million, respectively, and is reflected in Prepaid expenses and other current assets.

SEC original ↗Spyre Therapeutics, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Series A Non-Voting Convertible Preferred Stock Pursuant to the Company's Certificate of Designation of Preferences, Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock (the Series A Certificate of Designation ), holders of Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock equal to, on an as-if-converted-to-common stock basis, and in the same form as, dividends actually paid on shares of common stock.

SEC original ↗Spyre Therapeutics, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Series B Non-Voting Convertible Preferred Stock Pursuant to the Company's Certificate of Designation of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Stock (as amended, the Series B Certificate of Designation ), holders of Series B Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock equal to, on an as-if-converted-to-common stock basis, and in the same form as, dividends actually paid on shares of common stock.

SEC original ↗Spyre Therapeutics, Inc. — 10-Q Quarterly report10-QAug 4, 2026

The words believe, may, will, potentially, estimate, continue, anticipate, predict, target, intend, could, would, should, project, plan, expect, the negatives of these terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

SEC original ↗Spyre Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

In light of these risks, uncertainties, and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

SEC original ↗Spyre Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Aug 5, 2025

Legal Proceedings 36 Item 1A.

SEC original ↗Spyre Therapeutics, Inc. — 10-Q Quarterly report10-QAug 4, 2026

The words believe, may, will, potentially, estimate, continue, anticipate, predict, target, intend, could, would, should, project, plan, expect, and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

SEC original ↗Spyre Therapeutics, Inc. — 10-Q Quarterly report10-QAug 4, 2026

In light of these risks, uncertainties, and assumptions, the forward-looking events and circumstances discussed in this Quarterly Report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

SEC original ↗Spyre Therapeutics, Inc. — 10-Q Quarterly report10-QAug 4, 2026